The effect of eribulin treatment for patients with HER2-low breast cancer

被引：0
|
作者：
Goto, Wataru
Henmi, Saeko
Nishikawa, Mariko
Kouchi, Asuka
Kouhashi, Rika
Yabumoto, Akimichi
Takada, Koji
Asano, Yuka
Tauchi, Yukie
Ogisawa, Kana
Morisaki, Tamami
Kashiwagi, Shinichiro
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-05-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-05-11
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The impact of the HER2-low status on conditional survival in patients with breast cancer
    Ma, Teng
    Liu, Changgen
    Ma, Tianyi
    Sun, Xinyi
    Cui, Jian
    Wang, Lulu
    Mao, Yan
    Wang, Haibo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [22] Retrospective analysis of HER2-low in young breast cancer patients.
    Omar, Abeid Mohamed Athman
    Darwish, Azza Mohamad Amin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
    Yi, Xiaoli
    Hu, Shasha
    Ma, Meili
    Huang, Dongshuai
    Zhang, Yan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (04): : 880 - 890
  • [24] Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
    Xiaoli Yi
    Shasha Hu
    Meili Ma
    Dongshuai Huang
    Yan Zhang
    Clinical and Translational Oncology, 2024, 26 : 880 - 890
  • [25] Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness
    Zhao, Wei
    Zhang, Mingxiang
    Zhu, Bohui
    Pan, Yueyin
    Sun, Yiyuan
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2025, 34 (03) : 241 - 254
  • [26] Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer
    Devon K. Check
    Bradford E. Jackson
    Katherine E. Reeder-Hayes
    Michaela A. Dinan
    Eleanor Faherty
    Jackie Kwong
    Sandhya Mehta
    Lisa Spees
    Stephanie B. Wheeler
    Lauren E. Wilson
    Clara Lam
    Breast Cancer Research and Treatment, 2024, 203 : 329 - 338
  • [27] Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
    Guarneri, Valentina
    Coelho, Jose Luis Passos
    Duhoux, Francois P.
    Egle, Daniel
    Garcia-Saenz, Jose angel
    Penault-Llorca, Frederique
    Selander, Katri
    Wildiers, Hans
    Zaman, Khalil
    Laeis, Petra
    Lucerna, Markus
    Pierga, Jean-Yves
    FUTURE ONCOLOGY, 2024, 20 (18) : 1237 - 1250
  • [28] Selecting patients with HER2-low breast cancer: Getting out of the tangle
    Baez-Navarro, Ximena
    Salgado, Roberto
    Denkert, Carsten
    Lennerz, Jochen K.
    Penault-Llorca, Frederique
    Viale, Giuseppe
    Bartlett, John M. S.
    van Deurzen, Carolien H. M.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 187 - 192
  • [29] Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer
    Check, Devon K.
    Jackson, Bradford E.
    Reeder-Hayes, Katherine E.
    Dinan, Michaela A.
    Faherty, Eleanor
    Kwong, Jackie
    Mehta, Sandhya
    Spees, Lisa
    Wheeler, Stephanie B.
    Wilson, Lauren E.
    Lam, Clara
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 329 - 338
  • [30] A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm
    Roy, Arya Mariam
    Kumarasamy, Vasanthan Muthusamy
    Dhakal, Ajay
    O'Regan, Ruth
    Gandhi, Shipra
    CANCER, 2023, 129 (18) : 2773 - 2788
12345